Patents Assigned to Affectis Pharmaceuticals AG
-
Patent number: 8815892Abstract: The present application is directed to novel P2X7R antagonists that are indol-3-carboxamide or azaindole-3-carboxamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.Type: GrantFiled: July 24, 2012Date of Patent: August 26, 2014Assignee: Affectis Pharmaceuticals AGInventor: Michael Bös
-
Patent number: 8569334Abstract: The present application is directed to novel P2X7R antagonists that are indol-3-carboxamide or azaindole-3-carboxamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.Type: GrantFiled: July 13, 2012Date of Patent: October 29, 2013Assignee: Affectis Pharmaceuticals AGInventor: Michael Bös
-
Publication number: 20130197046Abstract: The present application is directed to novel P2X7R antagonists that are indol-3-carboxamide or azaindole-3-carboxamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.Type: ApplicationFiled: July 24, 2012Publication date: August 1, 2013Applicant: Affectis Pharmaceuticals AGInventor: Michael Bös
-
Publication number: 20130060047Abstract: Disclosed are novel methods for the synthesis of N-substituted indol-3-yl-alkylamide compounds which act as P2X7R antagonists, said methods involving the rearrangement of an oxime intermediate.Type: ApplicationFiled: March 4, 2011Publication date: March 7, 2013Applicant: AFFECTIS PHARMACEUTICALS AGInventor: Michael Bos
-
Publication number: 20120302597Abstract: The present application is directed to novel P2X7R antagonists that are indol-3-carboxamide or azaindole-3-carboxamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.Type: ApplicationFiled: July 13, 2012Publication date: November 29, 2012Applicant: AFFECTIS PHARMACEUTICALS AGInventor: Michael Bös
-
Patent number: 8268861Abstract: The present application is directed to novel P2X7R antagonists that are N-indol-3-yl-acetamide and N-azaindol-3-yl-acetamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.Type: GrantFiled: February 25, 2011Date of Patent: September 18, 2012Assignee: Affectis Pharmaceuticals AGInventor: Michael C Boes
-
Patent number: 8232290Abstract: The present application is directed to novel P2X7R antagonists that are indol-3-carboxamide or azaindole-3-carboxamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.Type: GrantFiled: March 25, 2009Date of Patent: July 31, 2012Assignee: Affectis Pharmaceuticals AGInventor: Michael Bös
-
Publication number: 20110212992Abstract: The present application is directed to novel P2X7R antagonists that are N-indol-3-yl-acetamide and N-azaindol-3-yl-acetamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.Type: ApplicationFiled: February 25, 2011Publication date: September 1, 2011Applicant: AFFECTIS PHARMACEUTICALS AGInventor: Michael BOES
-
Patent number: 7919503Abstract: The present application is directed to novel P2X7R antagonists that are N-indol-3-yl-acetamide and N-azaindol-3-yl-acetamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.Type: GrantFiled: April 12, 2010Date of Patent: April 5, 2011Assignee: Affectis Pharmaceuticals AGInventor: Michael Boes
-
Publication number: 20100267762Abstract: The present application is directed to novel P2X7R antagonists that are N-indol-3-yl-acetamide and N-azaindol-3-yl-acetamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.Type: ApplicationFiled: April 12, 2010Publication date: October 21, 2010Applicant: AFFECTIS PHARMACEUTICALS AGInventor: MICHAEL BOES
-
Patent number: 7767398Abstract: Nucleic acid molecules encoding an ATP-gated ion channel P2X7R which contains a mutation or a deletion are disclosed. Polypeptides encoded by the nucleic acid molecules and antibodies that specifically are directed to these polypeptides are disclosed. Aptamers that specifically bind the nucleic acid molecules, and primers for selectively amplifying the nucleic acid molecules are provided, kits, compositions, particularly pharmaceutical and diagnostic compositions comprising the nucleic acid molecules, vectors, polypeptides, aptamers, antibodies and/or primers, are provided. Methods for diagnosing affective disorders associated with a non-functional P2X7R protein, an altered ATP-gating of the P2X7R protein, an over- or underexpression of the P2X7R protein or associated with the presence of any one of the nucleic acid molecules or polypeptides encoded thereby are disclosed.Type: GrantFiled: May 16, 2007Date of Patent: August 3, 2010Assignee: Affectis Pharmaceuticals AGInventors: Nicholas Barden, Inge Sillaber, Marcelo Paez-Pereda
-
Publication number: 20090312366Abstract: The present application is directed to novel P2X7R antagonists that are indol-3-carboxamide or azaindole-3-carboxamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.Type: ApplicationFiled: March 25, 2009Publication date: December 17, 2009Applicant: AFFECTIS PHARMACEUTICALS AGInventor: Michael Bös